Preview Mode Links will not work in preview mode

ETF Spotlight


Jun 3, 2019

The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.

(1:00) - What Can Investors Learn From the ASCO Annual Meeting?

(5:45) - What Is Immunotherapy and What Are The Benefits?

(12:15) - What Companies Are Leading The Way?

(17:50) - AstraZeneca's Early Stage Cancer Treatments 

(21:00) - Recent Merger and Acquisitions For Biopharmaceutical Industry 

(23:25) - Loncar Cancer Immunotherapy ETF: CNCR

(26:40) - Policy Concerns Impacting The Healthcare Sector
Podcast@Zacks.com